Analytical Data
-
基因名
BCL2A1
-
简介
The BCL2A1 protein plays a critical role in resisting apoptosis triggered by IL-3 deprivation, suggesting its importance in the response of hematopoietic cells to external signals and may be involved in protecting endothelial cell survival during infection. It also inhibits serum starvation-induced apoptosis in mammary epithelial cells (HC11). BCL2A1 Protein, Human (His) is the recombinant human-derived BCL2A1 protein, expressed by E. coli , with N-His labeled tag.
- Application
-
别名
Bcl-2-related protein A1; Protein BFL-1; BCL2L5; BFL1; GRS; HBPA1
-
种属
Human
-
表达系统
E. coli
-
标签
N-6*His
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
Q16548
-
表达区间
M1-S152
-
蛋白长度
Partial
-
分子量
16-17 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
BCL2A1, a member of the Bcl-2 family of proteins, plays a crucial role in regulating apoptosis and cell survival, making it a significant focus of cancer research. This protein is known to inhibit apoptosis by preventing the mitochondrial release of cytochrome c and the activation of caspases, which are essential for the execution of programmed cell death. Abnormal expression of BCL2A1 has been linked to various cancers, including breast, prostate, and others, where it contributes to tumorigenesis by promoting cell survival in the presence of stress signals, such as chemotherapeutic agents. As cancer therapies aim to induce apoptosis in malignant cells, understanding the functional mechanisms of BCL2A1 becomes vital. Research into BCL2A1 often involves the production of recombinant proteins to study their structural and functional properties, as well as their interactions with other apoptotic regulators. These studies help clarify the role of BCL2A1 in the apoptotic pathway and its potential as a therapeutic target. Inhibiting BCL2A1 could enhance the efficacy of existing cancer therapies, thereby improving treatment outcomes. Consequently, the development of BCL2A1-targeted strategies is an area of active investigation in cancer biology, emphasizing the need for comprehensive studies involving its recombinant expression, characterization, and modulation in different cellular contexts.
